FDA Approves New Sunscreen Chemical Bemotrizinol
Published Date: 6/10/2026
Notice
Summary
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Manufacturers May Market Bemotrizinol Products Without New NDA
Under the final order (OTC000039) issued June 10, 2026, sunscreen products containing bemotrizinol that conform to the amended OTC Monograph M020 conditions (including concentration limits, permitted combinations, and permitted dosage forms) may be legally marketed without an approved application under section 505 of the FD&C Act. This enables sunscreen makers to offer bemotrizinol formulations under the OTC monograph pathway if they follow the specified conditions.
Bemotrizinol Added to OTC Sunscreens
The FDA amended OTC Monograph M020 on June 10, 2026 to add bemotrizinol as a recognized sunscreen active ingredient. You can now expect sunscreens to include bemotrizinol at concentrations up to 6 percent if the product meets the monograph conditions.
Spray Sunscreen Propellant Safety Requirement
The final order permits spray sunscreen dosage forms containing bemotrizinol only if they are manufactured and packaged with no propellant, or in a spray system where all propellant is isolated from the drug product and does not contact the formulation. This requirement is part of the amended OTC Monograph M020 effective June 10, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11429 — Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.
2026-11302 — Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
2026-11303 — Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
2026-11306 — Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi-Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis
The FDA is officially putting the shoulder joint humeral ceramic head/metallic stem prosthesis into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps patients get safer, innovative shoulder implants faster and makes life easier for makers by lowering regulatory costs. The new classification is effective June 5, 2026, but has been in effect since December 16, 2022.
2026-11308 — Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
Previous / Next Documents
Previous: 2026-11575 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Trademark Trial and Appeal Board (TTAB) Actions
The USPTO is asking for public feedback on continuing to collect info about Trademark Trial and Appeal Board (TTAB) actions, which affect businesses and individuals dealing with trademarks. This is a routine step to keep paperwork in check and won’t change fees or deadlines. You’ve got until August 10, 2026, to share your thoughts before the government gives the final thumbs-up.
Next: 2026-11579 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to U.S. Army Corps of Engineers Miller Sands Island, Rice Island, and Cottonwood Island Pile Dike Repairs Projects on the Lower Columbia River in Oregon and Washington
The U.S. Army Corps of Engineers got permission to do pile dike repairs on Miller Sands, Rice, and Cottonwood Islands along the Lower Columbia River. This work might accidentally disturb some marine mammals, but it’s allowed because it won’t harm their populations. The projects will run for up to one year starting June 2026, helping keep the river safe and healthy without breaking any rules.